#United States #Nashville #Cumberland Pharmaceuticals #Vibativ #Caldolor

Cumberland Pharmaceuticals Sees 23% Revenue Growth Year-to-Date

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a Nashville-based specialty pharmaceutical company, has recently announced impressive financial results, marking a remarkable 23% increase in year-to-date revenues. The company reported net revenues of $22.6 million for the first half of 2025, driven primarily by its robust portfolio of FDA-approved medications.

Second Quarter Highlights

In the second quarter alone, Cumberland generated net revenues of $10.8 million, reflecting a 10% growth compared to the same period last year. This revenue growth can be attributed to various products in its portfolio, including Vibativ®, Caldolor®, Kristalose®, and Sancuso®, all of which contributed positively to the company’s bottom line. Specifically, revenues for each product were:

• - Vibativ®: $2.7 million
• - Caldolor®: $1.6 million
• - Kristalose®: $2.8 million
• - Sancuso®: $3.1 million

These figures speak to the solid demand for Cumberland’s offerings, further cementing its reputation in the specialty pharmaceuticals market.

Strong Balance Sheet

As of June 30, 2025, Cumberland reported total assets of approximately $68 million, with liabilities totaling $40 million and shareholders' equity amounting to $28 million. This healthy balance sheet illustrates the company’s effective management and financial stability. CEO A.J. Kazimi expressed optimism about the company's ongoing clinical development programs and upcoming growth potential.

Recent Developments

Cumberland has made significant strides this year with several key developments:

• - Vibativ® 4-Vial Starter Pak: The recent partnership with Vizient Inc. has made Vibativ® available to healthcare providers nationwide, enhancing treatment options for patients suffering from serious bacterial infections.
• - Clinical Analysis of Vibativ: A recent pharmacokinetic analysis published in Antimicrobial Agents and Chemotherapy supported the product’s dosing strategies, reinforcing its efficacy in treating life-threatening gram-positive infections.
• - Ifetroban Research: Promising data from Phase II trials of ifetroban in treating Duchenne muscular dystrophy (DMD) were presented at a recent muscular dystrophy conference, illustrating a 5.4% improvement in cardiac function among high-dose patients.

Cumberland continues to expand its clinical programs, including ongoing trials for ifetroban in systemic sclerosis and idiopathic pulmonary fibrosis, representing its commitment to addressing serious unmet medical needs.

Financial Outlook

Despite reporting a net loss of approximately $741,000 in the second quarter, Cumberland’s adjusted earnings for the first half stood at $2.8 million, equivalent to $0.18 per diluted share. This reflects a judicious approach to managing operating expenses, which totaled $11.6 million for the second quarter. The company is cautiously optimistic about its financial trajectory going forward.

Earnings Conference Call

To discuss these developments and financial results in detail, Cumberland Pharmaceuticals held a conference call on August 5, 2025. This interactive session provided insights into the company’s ongoing initiatives and market strategies, emphasizing transparency and shareholder engagement.

Cumberland Pharmaceuticals remains focused on delivering innovative products to improve patient care, reinforcing its position in the pharmaceutical industry. With a promising portfolio and active clinical trials underway, the company is positioning itself for continued success in meeting the evolving needs of the healthcare market.